Power Calculations for Replication Studies by Micheloud, Charlotte & Held, Leonhard
Power Calculations for Replication Studies
Charlotte Micheloud and Leonhard Held
Epidemiology, Biostatistics and Prevention Institute (EBPI)
and Center for Reproducible Science (CRS)
University of Zurich
Hirschengraben 84, 8001 Zurich, Switzerland
Email: charlotte.micheloud@uzh.ch
Friday 24th April, 2020
Abstract: The reproducibility crisis has led to an increasing number of repli-
cation studies being conducted. Sample sizes for replication studies are often
calculated using conditional power based on the effect estimate from the orig-
inal study. However, this approach is not well suited as it ignores the uncer-
tainty of the original result. Bayesian methods are often used in clinical trials
to incorporate prior information into power calculations. We propose to adapt
this methodology to the replication framework and to use predictive instead
of conditional power. Moreover, we describe how the methodology used in
sequential clinical trials can be tailored to replication studies. The predictive
interim power, i.e. the predictive power conditioned on the data already col-
lected, is shown to be useful to decide whether to stop a replication study at
interim. Predictive power generally leads to smaller values than conditional
power and does not always increase when increasing the sample size. Adding
more subjects to the replication study can in some cases decrease the predic-
tive power. We illustrate these properties using data from a recent project on
the replicability of social sciences.
Key Words: Replication Studies, Conditional Power, Predictive Power, Se-
quential Design, Interim Analysis.
1 Introduction
The replicability of research findings is essential for the credibility of science. However, the scientific world
is experiencing a crisis (Begley and Ioannidis, 2015) as the replicability rate of many fields appears to be
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alarmingly low. These fields comprise psychology (Open Science Collaboration, 2015; Johnson et al., 2017),
social sciences (Camerer et al., 2018) and economics (Camerer et al., 2016) among others. As a result, large
scale replication projects, where original studies are selected and replicated as closely as possible to the
original procedures, have gained increasing interest among researchers. Replication success is usually as-
sessed using significance and p-values, compatibility of effect estimates, subjective assessments of replica-
tion teams and meta-analysis of effect estimates (e. g. in Open Science Collaboration, 2015). The statistical
evaluation of replication studies is still generating much discussion and new standards are proposed (e. g.
in Patil et al., 2016; Ly et al., 2018; Held, 2020).
Yet before a replication study is analyzed, it needs to be designed. While the conditions of the replication
study are ideally identical to the original study, the replication sample size stands out as an exception and
requires further consideration. Using the same sample size as in the original study may lead to a severely
underpowered replication study, even if the original study correctly estimated the true effect size (Good-
man, 1992). Thus a commonly used approach is to perform standard power calculations using the effect
estimate from the original study as the basis for the replication study. The resulting power is called ‘condi-
tional’ as it is conditioned on an effect which is assumed to be the truth. A major criticism of this method
is that the uncertainty accompanying this original finding is ignored and so the resulting replication study
is likely to be underpowered (Anderson and Maxwell, 2017). In this paper, we propose alternatives based
on predictive power and adapted from Bayesian approaches to incorporate prior knowledge to sample size
calculation in clinical trials (Spiegelhalter et al., 2004).
In an era where an increasing number of replication projects are being undertaken, optimal allocation
of resources appears to be of particular importance. Adaptive designs are well suited for this purpose
and their relevance no longer needs to be justified, particularly in clinical trials. Continuing to collect data
whenever it is sufficiently clear that the effect we expected is not present is unethical at several levels.
In addition to a waste of money, this process also generates a waste of human resources and can have an
impact on human or animal lives. In clinical trials for example, continuing a study which should be stopped
can be a matter of life or death. The same applies to preclinical studies, where in addition animals could be
reallocated to other experiments and help to tackle the actual threat of underpowered studies in preclinical
biomedicine (Neumann et al., 2017). Stopping for futility refers to the termination of a trial when the data
at interim indicate that it is unlikely to achieve statistical significance at the end of the trial (Snapinn et al.,
2006). In contrast, stopping for efficacy arises when the data at interim are so convincing that there is no
need to continue collecting more data. One approach for assessing efficacy and futility is called stochastic
curtailment (Halperin et al., 1982). In this approach, the conditional power of the study, given the data so
far, is calculated for a range of alternative hypotheses. The results can then be summarized into plots or
tables and help towards the decision of stopping or continuing the data collection. Instead of conditional
power, predictive power can also be used to judge if a trial should be continued (Herson, 1979). This concept
has been discussed in depth in Dallow and Fina (2011) and Rufibach et al. (2016), with an emphasis on the
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choice of the prior in the latter.
Lakens (2014) points out that sequential replication studies could be an alternative to fixed sample size
calculations. However, adaptive designs for replication studies is a topic that has not been intensively
investigated in the literature. Camerer et al. (2018) conducted the Social Science Replication Project (SSRP)
where they informally performed an interim analysis but without adjusting the threshold for significance
or recalculating the power at the interim analysis. Moreover, only stopping for efficacy was considered
and no mention of futility stopping has been made. We try to fill this gap by proposing different methods
to calculate the interim power, namely the power of a replication study taking into account the data from
an interim analysis. We show that interim power is a useful tool to guide the decision to stop replication
studies where the intended effect is not present. For the time being our framework only enables power
calculation at a single interim analysis, but could in theory be extended to multiple analyses.
This paper consists of two main parts: power calculations for non-sequential (Section 3) and for se-
quential (Section 4) replication studies. The methods described in these sections are designed for normally
distributed outcomes. Relevant properties of these methods are then illustrated using data from the SSRP.
Section 2 provides a detailed description of this project. We close with some discussion in Section 5.
2 Data
The SSRP reports replication results of 21 experimental studies in the social sciences published in Nature
and Science between 2010 and 2015. The complete dataset with extended information is available at https:
//osf.io/pfdyw/. The effects are given as correlation coefficients, making them easily interpretable and
comparable. Moreover, the application of Fisher’s z transformation z(r) = tanh−1(r) to the correlation co-
efficients justifies an asymptotic normal distribution and the standard error of the transformed coefficients
becomes a function of the effective sample size n− 3 only, se(z) = 1/√n− 3. In this dataset, original effects
are always positive. A ready-to-use dataset SSRP can be found in the package ReplicationSuccess,
available at https://r-forge.r-project.org/projects/replication/.
2.1 Sample size calculation
Aware of the possible inflation of the original effect estimates, the authors of the SSRP adopted a two-stage
replication sample size calculation procedure. In stage 1, the replication studies had 90% power to detect
75% of the original effect estimate. Data collection was stopped if a two-sided p-value< 0.05 and an effect in
the same direction as the original effect were found. If not, data collection was continued in stage 2 to have
90% power to detect 50% of the original effect estimate for the first and second data collections pooled. This
dataset is relevant for our purpose as stages 1 and 2 can be considered as two parts of a sequential analysis,
with an interim analysis in between. In our framework, the analysis after stage 1 will be called the interim
analysis while the final analysis will refer to the analysis based on the pooled data from stages 1 and 2.
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2.2 Descriptive results
Twelve studies were significant at interim with an effect in the correct direction but by mistake only eleven
were stopped. Out of the ten studies that were continued, only two showed a significant result in the correct
direction at the final analysis. The study that was wrongly continued turned out to be non-significant at the
final analysis. Figure 1 provides a visual representation of the results.
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Figure 1: Original effect estimate vs. replication effect estimate (on the correlation scale). Replications which
were not pursued in stage 2 are included with the results from stage 1. Shape and color of the point indicate
whether the study was stopped due to a significant result in the correct direction at interim (green triangle),
at the final analysis (red circle) or the study did not find a significant effect in the correct direction (black
square). The diagonal line indicates replication effect estimates equal to original effect estimates. The two
studies indicated with an arrow are investigated more extensively in this paper and are described in Table 1.
2.3 A closer look at two studies
Two studies of the SSRP will be investigated in more detail (see Table 1). These are the studies originally
from Shah et al. (2012) and Nishi et al. (2015). Let n denote the sample size, p the two-sided p-value, r the
correlation coefficient and the subscripts o, i and r respectively indicate original, interim and replication
(final analysis).
Original Interim Replication
Study no po ro ni pi ri nr pr rr
Shah 56 0.046 0.27 278 0.15 -0.09 619 0.7 -0.02
Nishi 200 0.004 0.20 480 0.01 0.12
Table 1: Details of two studies of the SSRP dataset
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The replication from Shah et al. (2012) was not significant at interim (pi = 0.15) and even had an effect
going in the opposite direction (ri = -0.09). This study was therefore continued and finally failed to replicate
(pr = 0.7 and rr = -0.02). In contrast, the replication from Nishi et al. (2015) had a two-sided p-value smaller
than 0.05 at interim (pi = 0.01) with an effect going in the correct direction (ri = 0.12). Data collection for
this study was thus stopped after the interim analysis and the replication was declared successful. We will
come back to these two studies later in the applications (Sections 3.2 and 4.2).
3 Non-sequential replication studies
In the SSRP, as well as in most replication projects, power calculations for the replication studies are based
on the effect estimate from the original study and ignore the surrounding uncertainty. In order to incorpo-
rate the uncertainty of the original result in the power and sample size calculation of the replication study,
we use the following prior for the true effect size θ,
θ ∼ N
(
θˆo, σ
2
o = σ2/no
)
, (1)
centered around the original effect estimate θˆo (assumed to be positive) and with variance inversely propor-
tional to the original sample size no (Spiegelhalter et al., 2004). We denote by σ2 the known unit variance
from one observation and σ2o = σ2/no is the variance of the estimate θˆo. Similarly, the effect estimate
from the replication study is denoted by θˆr and its variance by σ2r = σ2/nr. In what follows, the different
formulas resulting from the use of the prior (1) are described. Proofs and additional information related
to this section can be found in Appendix A. This section is inspired by Section 6.5 in Spiegelhalter et al.
(2004) where Bayesian contributions to selecting the sample size of a clinical trial are studied. We adapt this
methodology to the replication framework and express the power calculation formulas in terms of unitless
quantities (namely relative sample sizes and test statistics).
3.1 Methods
We differentiate between the design and the analysis prior, both having an impact on the power calculation
(O’Hagan and Stevens, 2001). The design prior is used before the data are collected in order to quantify prior
beliefs about the true effect size (Schönbrodt and Wagenmakers, 2018). It contributes to the study design
but is not used in the subsequent statistical analysis. The fact that prior information can also be included in
the analysis is not well-known. A flat analysis prior corresponds to a classical frequentist analysis, while an
informative analysis prior indicates a Bayesian analysis (O’Hagan and Stevens, 2001), where original and
replication results are pooled. The different combinations of design and analysis priors are shown in Table
2.
A point prior at θ = θˆo in the design indicates the ignorance of the uncertainty and corresponds to the
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Design
Point prior Normal prior (1)
A
na
ly
si
s Flat
prior Conditional Predictive
Normal
prior (1) Conditional Bayesian Fully Bayesian
Table 2: Methods of power calculations resulting from the different combinations of design and analysis
priors.
concept of conditional power (Spiegelhalter et al., 1986; Spiegelhalter and Freedman, 1986). In such cases,
the probability of a positive result in the replication study is conditioned on the effect estimate from the
original study. In contrast, the normal design prior incorporates the accompanying uncertainty and is re-
lated to the concept of predictive power, which averages the conditional power over the possible values
of the true effect according to its prior distribution (Spiegelhalter et al., 1986; Spiegelhalter and Freedman,
1986). Alternative names for predictive power in the literature are assurance (O’Hagan et al., 2005), prob-
ability of study success (Wang et al., 2013) and Bayesian predictive power (Spiegelhalter et al., 1986). The
conditional and predictive power are usually accompanied by a flat analysis prior, but can also be cal-
culated assuming the original and replication studies are pooled (normal analysis prior), resulting in the
conditional Bayesian power and the fully Bayesian power, respectively. A schematic representation of these
four power calculation methods can be found in Figure 2.
3.1.1 Conditional power
Conditional power is the probability that a study with n observations will lead to a statistically significant
conclusion at the α level, given that the alternative hypothesis is true (Spiegelhalter et al., 2004, Section 2.5).
In the context of a replication study, the alternative hypothesis is represented by the effect estimate θˆo from
the original study.
Let zα/2 and Φ[·] respectively denote the α/2-quantile and the cumulative distribution function of the
standard normal distribution. The conditional power is
CP = Φ
[
θˆo
√
nr
σ
+ zα/2
]
, (2)
see Appendix A.1 for a derivation. The minimum clinically important difference in the context of clinical
trials is replaced in (2) by the effect estimate θˆo from the original study. The required replication sample
size nr can be obtained by rearranging (2).
A key feature of our framework is the independence of all power/sample size formulas from absolute
effect measures. Simple mathematical rearrangements produce an expression which only depends on the
original test statistic to = θˆo/σo = θˆo
√
no/σ and the variance ratio c = σ2o/σ2r = (σ2/no)/(σ2/nr). The
variance ratio c simplifies to the relative sample size c = nr/no and represents how much the sample size
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Figure 2: Schematic representation of power calculations for non-sequential replication studies. The dashed
line means that the replication study has not been conducted yet. The estimate θˆo with black or grey con-
fidence interval indicates whether its uncertainty is taken into account in the power calculation or not,
respectively. A classical analysis of the results (flat analysis prior) is indicated by two separates lines for
original and replication studies while a continuous line indicates a Bayesian analysis of the results (normal
analysis prior).
in the replication study is increased as compared to the one in the original study. Formula (2) then becomes
CP = Φ
[√
c to + zα/2
]
. (3)
This formula highlights a very intuitive property of the conditional power: the larger the evidence in the
original study (quantified by to) or the larger the increase in sample size compared to the original study
(represented by c), the larger the conditional power of the replication study.
3.1.2 Predictive power
The previous method calculates the power conditional on the effect from the original study, which is as-
sumed to be the true effect. This assumption is questionable, as the original effect estimate θˆo is an estimate
of the true effect and hence comes with its uncertainty. In order to incorporate this uncertainty while still
performing a classical analysis, the concept of predictive power is discussed (Spiegelhalter and Freedman,
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1986). The formula for the predictive power is:
PP = Φ
[√
no
no + nr
(
θˆo
√
nr
σ
+ zα/2
)]
,
see Appendix A.2 for a derivation. Using the unitless quantities to and c, the predictive power can be
rewritten as
PP = Φ
[√
c
c+ 1 to +
√
1
c+ 1 zα/2
]
. (4)
The predictive power tends to the conditional power as the original sample size increases. This is reasonable
since the prior variance in (1) tends to zero as the uncertainty of θˆo tends to zero and the normal prior
becomes then a point prior at θ = θˆo. Unlike the conditional method, the predictive method has no closed-
form expression for the relative sample size c given a fixed predictive power. Iterative application of root-
finding algorithms is required.
3.1.3 Fully Bayesian and conditional Bayesian power
So far two power calculation methods where the analysis is performed in a classical way have been con-
sidered. This approach fits the replication framework as a replication study should be an independent
repetition of an original study being questioned. In view of that, a Bayesian analysis where original and
replication results are pooled seems less suitable. However, a pooled analysis has interesting properties
and is worth a short mention.
The fully Bayesian power is calculated using the prior (1) in both the design and the analysis. Using
the same prior beliefs in both stages is considered as the most natural approach by some authors (e. g. in
O’Hagan and Stevens, 2001). The corresponding formula is
FBP = Φ
[√
c+ 1
c
to +
√
1
c
zα/2
]
. (5)
Note that the fully Bayesian power is also a predictive power as it incorporates the uncertainty of the
original effect estimate θˆo.
The last possible combination of design and analysis priors is ignoring the uncertainty of the original
result in the design, while still performing a Bayesian analysis. We call the resulting power the conditional
Bayesian power:
CBP = Φ
[
c+ 1√
c
to +
√
c+ 1
c
zα/2
]
. (6)
The derivations can be found in Appendix A.3 and A.4.
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3.1.4 Inflated original findings
The issue of overestimated original findings is widely known and can have several causes (Ioannidis, 2008;
Button et al., 2013; Anderson and Maxwell, 2017). In the SSRP, replication effect estimates were about
50% of the original effect estimates (see Figure 1). A simple way to correct for this inflation in all power
calculations is to shrink the original effect estimate θˆo or equivalently the original test statistic to by a factor
between 0 and 1. This shrinkage approach has been used in the SSRP. More advanced methods using a
data-driven approach with empirical Bayes (Pawel and Held, 2020) are not considered here.
3.2 Application
We now discuss properties of the four power formulas described in Section 3.1 using the SSRP data. In
Figure 3, the conditional, predictive, conditional Bayesian and fully Bayesian power of the 21 replication
studies is shown. The replication sample size considered in the calculations is the one used by the authors
in stage 1, ignoring stage 2. To be consistent with the paper, the original effect estimates are shrunken to
75% of their reported value in the calculations. The two studies of Table 1 are then considered in more
detail and the power as a function of the relative sample size c (see Figure 4) is being discussed. We are
aware that the range of relative sample sizes c shown in Figure 4 is extremely wide and relative sample
sizes are in practice more likely to be between c = 0.5 and c = 10. However, some interesting theoretical
properties of the different methods can be observed only for very small or very large c. In our examples a
two-sided 5% significance level is assumed. Because our calculations are based on Fisher’s z-transformed
correlation coefficients, the effective sample sizes are used and the relative sample size therefore becomes
c = (nr − 3)/(no − 3).
3.2.1 Conditional vs. predictive power
Figure 3 is in agreement with well-known results from the literature (Spiegelhalter et al., 2004; Grouin
et al., 2007; Dallow and Fina, 2011): predictive methods generally lead to a smaller power than conditional
methods. This is the case for all 21 studies of this dataset. The conditional power is larger than the predictive
power; and the conditional Bayesian power larger than the fully Bayesian power. However, the situation is
reversed when the conditional power is smaller than 50%. In this case, the predictive power is larger than
the conditional power; and the fully Bayesian power larger than the conditional Bayesian power.
Power can also be studied as a function of the relative sample size c. It can be shown that conditional
and predictive power are both equal to 50% if the relative sample size is
c = z2α/2/t2o , (7)
the squared α/2-quantile of the normal distribution divided by the squared test statistic from the original
study (see Appendix A.5 for details). Equation (7) implies that the larger the evidence in the original study
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Figure 3: Replication power with the conditional, the predictive, the conditional Bayesian and the fully
Bayesian methods for the 21 studies of the SSRP. Each circle represents a study and the lines link the same
studies.
(quantified by to), the smaller the relative sample size c where conditional and predictive power curves
intersect. This can be observed in Figure 4, where the relative sample size corresponding to the intersection
of the conditional and predictive power curves is closer to zero in the replication of Nishi et al. (2015) as
the original study is more convincing than in Shah et al. (2012). It can also be shown that the fully Bayesian
power and conditional Bayesian power are crossing at a power of 50% with corresponding relative sample
size
c = z2α/2/t2o − 1 . (8)
However, this cannot be observed in Figure 4 as Equation (8) shows that the two curves intersect at a
positive value of c only when the original study is not significant (z2α/2 ≥ t2o). Otherwise, the conditional as
well as the fully Bayesian power are larger than 50% for every c ≥ 0.
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Figure 4: Replication power as a function of the relative sample size c for two studies of the SSRP. The
horizontal red line indicates a power of 50%. The vertical grey line corresponds to the intersection of
the conditional and predictive power curves as calculated in (7). The horizontal and vertical purple lines
indicate the minimum Bayesian power (see (9)) and the corresponding relative sample size c as in (10),
respectively. The brown horizontal line indicates 1− po/2.
3.2.2 Predictive power cannot always reach 100%
Unlike the conditional power which always reaches 100% for a sufficiently large replication sample size,
the predictive power has an asymptote at 1 − one-sided original p-value (see Appendix A.6 for details).
This means that the more convincing the original study, the closer to 100% the power of an infinitely large
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replication study is. In a sense, the original result penalizes the predictive power. However, this penalty is
not very stringent, as replication of an original study with a two-sided p-value of 0.05 would still be able to
reach a predictive power of 97.5% for a sufficiently large replication sample size. This property also applies
to the fully Bayesian power and can be observed in Figure 4 where the brown horizontal line indicates
1− po/2.
3.2.3 Bayesian analysis: pooling original and replication results
In this paragraph, relevant features of the fully Bayesian power as a function of the relative sample size
c are being discussed. The fully Bayesian power behaves differently depending on the significance of the
original study. For a non-significant original study (po > α = 0.05 in our examples), the fully Bayesian
power converges to 0% for c → 0 and monotonically increases as the relative sample size c increases. In
contrast, for a significant original study (po < 0.05), the power converges to 100% for c → 0, decreases
down to
Φ
[√
t2o − z2α/2
]
(9)
for increasing c and then increases to 1 − po/2. The relative sample size corresponding to the minimum
fully Bayesian power (9) is
c = t2o/z2α/2 − 1 . (10)
See Appendix A.7 for a derivation. This implies that a highly convincing original study (represented by a
large to) will always have a fully Bayesian power very close to 100% independently of the sample size. This
emphasizes why a Bayesian analysis is not suitable if we want the replication to be independent from the
original study. Both studies investigated in Figure 4 have a significant original finding, leading to a Bayesian
power larger than 50% for all values of c (as explained in 3.2.1). Moreover, the minimum Bayesian power
is smaller and corresponds to a smaller value of c in the replication of Shah et al. (2012) as compared to the
replication of Nishi et al. (2015) as the evidence is larger in the latter. The derivations for the conditional
Bayesian method are omitted as they are intricate and do not bring much additional insights.
4 Sequential replication studies
In Section 3, power calculations are performed before any data have been collected in the replication study.
This framework is extended in this section and allows power (re)calculation at an interim analysis, after
some data have been collected in the replication study already. The interim power is the power of a replica-
tion study taking into account the data from an interim analysis. This implies that independently of the method
used, the interim power is conditioned on the data already observed in the replication study. If there is
none, then the power at interim reduces to the power of non-sequential replication studies as discussed in
Section 3. The approach of incorporating prior knowledge into interim power has been studied in Spiegel-
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halter et al. (2004, Section 6.6) and we adapt this concept to the case where prior information refers to a
single original study. Moreover, the power calculation formulas are expressed in terms of unitless quanti-
ties (namely relative sample sizes and test statistics) in our work.
4.1 Methods
Similarly to what is described in Section 3.1, the concepts of design and analysis priors also play a role in
this section. The normal prior refers to (1) and the point prior to the point estimate θ = θˆo. In addition
to these two priors, this new framework enables the specification of a flat design prior. This refers to a
situation where the original study is ignored in the interim power calculation. Table 3 shows the different
types of interim power calculations that are investigated in this section.
Design
Point prior Normal prior (1) Flat prior
A
na
ly
si
s Flat
prior Conditional Informed predictive Predictive
Normal
prior (1) - Fully Bayesian -
Table 3: Methods of interim power calculations resulting from different combinations of design and analysis
priors.
Calculating the interim power conditioned on the effect estimate from the original study ignores the
uncertainty of the original result. This corresponds to the conditional power in Table 3. Uncertainty of
the original results can be taken into account when recalculating the power at an interim analysis, turning
the conditional power into a predictive power (Spiegelhalter et al., 2004; DeMets, 2006). This requires
the selection of a prior distribution for the true effect, which is modified by the data collected so far in
the replication study to give rise to a posterior distribution. The prior distributions discussed here are
the normal prior (1) (leading to the informed predictive power) and a flat prior (leading to the predictive
power). The conditional power is then averaged with respect to the posterior distribution of the true effect
size, given the data already observed in the replication study. This framework also enables the specification
of an informative prior in the analysis, leading to a pooled analysis (second row in Table 3). However,
we know from Section 3 that this type of analysis is not desired in the present context. The fully Bayesian
power at interim is mentioned here for illustrative purposes and is not further discussed. Its formula can be
found in Appendix B.4. The other two power methods using a Bayesian analysis are omitted here. Figure 5
shows a schematic representation of the power calculation methods.
Let θˆi be the effect estimate at interim and σ2i = σ2/ni the corresponding variance, with ni the sample
size at interim. The sample size that is still to be collected in the replication study is denoted by nj and
the total replication sample size is thus nr = ni + nj . The interim power formulas can be shown to only
depend on the original and interim test statistics to and ti (ti being θˆi/σi = θˆi
√
ni/σ), the relative sample
size c = nr/no and the variance ratio f = σ2r/σ2i = (σ2/nr)/(σ2/ni). The variance ratio f simplifies to the
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Figure 5: Schematic representation of power calculations for sequential replication studies. The dashed line
represents the fraction of the replication study that has not been conducted yet. The estimate θˆo with black
or grey confidence interval indicates whether its uncertainty is taken into account in the interim power
calculation or not, respectively. A classical analysis of the results (flat analysis prior) is indicated by two
separates lines for original and replication studies while a continuous line indicates a Bayesian analysis of
the results (normal analysis prior).
fraction f = ni/nr of the replication study already completed. Proofs and additional information related to
this section can be found in Appendix B.
4.1.1 Conditional power at interim
The conditional power at interim is the interim power conditioned on the effect estimate from the original
study. It can be expressed as
CPi = Φ
[√
c(1− f) to +
√
f
1− f ti +
√
1
1− f zα/2
]
, (11)
see Appendix B.1 for a derivation. In the particular case where no data has been collected yet in the repli-
cation study (f = 0), the conditional power at interim reduces to the conditional power (2) at the start of
the replication study. Instead of the original effect estimate, the power could be conditioned on the effect
estimate observed at interim or on a combination of original and interim effect estimates (Bauer and König,
2006; Spiegelhalter et al., 2004). However, common practice is to condition on the originally specified alter-
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native hypothesis if it has been chosen as the minimum clinically important difference, irrespectively of the
interim result (Dallow and Fina, 2011). This is the approach considered here.
4.1.2 Informed predictive power at interim
The informed predictive power at interim is the predictive interim power using the design prior (1). It can
be formulated as
IPPi = Φ
[√
(1− f)c
(cf + 1)(1 + c) to +
√
f(1 + c)
(1− f)(cf + 1) ti +
√
cf + 1
(1 + c)(1− f) zα/2
]
, (12)
see Appendix B.2 for a derivation. In the case of f = 0 (no data collected in the replication study so far), the
informed predictive power at interim reduces to the predictive power (4) at the start of the replication study.
By considering the original result but also its uncertainty, the predictive power at interim is a compromise
between considering only the original effect estimate (CPi) and completely ignoring the original study (PPi)
in the design.
4.1.3 Predictive power at interim
The predictive power at interim is the predictive interim power using a flat design prior. In other words,
the results from the original study are ignored. It is expressed as
PPi = Φ
[√
1
1− f ti +
√
f
1− f zα/2
]
, (13)
see Appendix B.3 for a derivation. Note that the formula (13) corresponds to the Bayesian power formula
(5) provided that the original study in the Bayesian power formula is considered as the interim study (see
Appendix B.3). This illustrates well the dependence of original and replication studies when a Bayesian
analysis is applied.
4.2 Application
The SSRP studies are once more used to illustrate the characteristics of the methods introduced above.
The studies which have not been stopped at interim have been selected and their interim power has been
calculated with different methods (see Table 4). In addition, the informed predictive power at interim and
the predictive power at interim are presented in Figure 6 as a function of the fraction (1−f ) of the replication
sample size still to be collected for the two studies from Table 1 and for two hypothetical interim results.
Note that the plots of the predictive power at interim of Shah et al. (2012) and Nishi et al. (2015) are identical
as the PPi ignores the original result. A two-sided 5% significance level is used and effective sample sizes
are considered, meaning that c = (nr − 3)/(no − 3) and f = (ni − 3)/(nr − 3).
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Original Interim Replication Interim power
Study po ro f pi ri c pr rr CPi IPPi PPi
Duncan 0.005 0.67 0.37 0.29 0.18 7.42 0.00001 0.44 100.0 74.6 43.4
Pyc 0.023 0.38 0.43 0.09 0.15 9.18 0.009 0.15 100.0 85.3 71.0
Ackerman 0.048 0.27 0.43 0.02 0.14 11.69 0.125 0.06 100.0 95.0 90.3
Sparrow 0.002 0.37 0.44 0.27 0.11 3.50 0.451 0.05 99.7 74.1 40.1
Rand 0.009 0.14 0.47 0.37 0.03 6.27 0.234 0.03 99.8 51.9 27.0
Gervais 0.029 0.29 0.42 0.41 -0.05 9.78 0.415 -0.04 97.5 1.9 0.3
Kidd 0.012 0.27 0.40 0.27 -0.07 8.57 0.467 -0.03 98.9 1.6 0.1
Lee 0.013 0.39 0.42 0.45 -0.07 7.65 0.435 -0.05 97.7 3.1 0.4
Ramirez 0.000008 0.79 0.30 0.72 -0.08 4.47 0.390 -0.10 100.0 61.4 4.2
Shah 0.046 0.27 0.45 0.15 -0.09 11.62 0.710 -0.02 87.0 0.1 0.0
Table 4: Conditional power at interim (CPi), informed predictive power at interim (IPPi) and predictive
power at interim (PPi) of the ten studies that were continued including the original, interim and replication
two-sided p-values and effect estimates, the relative sample size c and the fraction f of the replication study
already completed.
4.2.1 Weights given to original and interim results
In each interim power formula, the weight given to original and interim results depends on the values of
c and f (see Appendix B.5). We will focus here on the situation with relative sample size c > 2 and < 50%
of the replication study completed (f < 0.5) as it is the case for all ten studies of Table 4. In this case, more
weight is given to the original result as compared to the interim result in the CPi formula. This explains
why the CPi is remarkably large for the ten studies, even when interim results are in the opposite direction
as the original results. In contrast, more weight is given to the interim results in the IPPi formulas, making
the corresponding power values more sensible. If a futility boundary of 10% had been used (as mentioned
in DeMets (2006)) four out of the eight studies which failed to replicate at the final analysis would have
been stopped at interim based on the IPPi values. The PPi ignores the original result in the calculation,
making the power solely dependent on the interim result. Using the 10% futility boundary, five out of the
eight studies which failed to replicate at the final analysis would have been stopped at interim with this
method.
4.2.2 A power of 100% cannot always be reached with the predictive methods
The conditional power at interim can reach 100% if the sample size to be collected in the replication study
(nj) is large enough. In our framework this means a relative sample size c tending to infinity and a frac-
tion f of the replication study already completed tending to 0. In contrast and similarly to the asymptote
of predictive power at the start of the replication study, the asymptote of predictive power at interim is
penalized by the original and/or interim results. The larger the evidence in the original study and at in-
terim (represented by to and ti, respectively), the larger the asymptote of the informed predictive power
(formula given in Appendix B.6). The asymptote of the predictive power at interim, on the other hand, is
1 − one-sided interim p-value. This last property is explained in Dallow and Fina (2011, Section 4). These
asymptotes are visualized in Figure 6. Remarkably, the maximum reachable PPi for a study with an interim
p-value of 0.5 is 75%.
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4.2.3 Non-monotonicity property of power
If the two-sided interim p-value is larger than α (5% in this case), then the interim power behaves in an
expected way: it increases with increasing sample size. However, this property breaks when pi < α. In this
situation, the power assuming no additional subject to be added (f = 1) is 100%, declines with increasing
nj (decreasing f ) and then increases. In this case, the minimum predictive power at interim can be shown
to be Φ
[√
t2i − z2α/2
]
which means that the PPi of any replication study with a significant interim result
will never be smaller than 50% (details in Appendix B.7). This property can be observed in Figure 6. The
same behavior also applies to the conditional power at interim (not shown here). Dallow and Fina (2011)
explain this characteristic as follows: "Intuitively, if the interim results are very good, any additional subject
can be seen as a potential threat, able to damage the current results rather than a resource providing more
power to our analysis." This result implies that if the interim result is significant, this replication study will
not to be stopped for futility. Also using this approach to assess an early stopping for efficacy is not optimal
as it will always stop if the interim result is significant at level α, without taking into account Type I error
inflation.
5 Discussion
Conditional power calculations appear to be the norm in most replication projects. The main goal of this
paper is to show that more can and has to be done to ensure well-powered replication studies. We discussed
the main problem of conditional power and outlined the rationale and properties of predictive power. In
contrast to conditional power, increasing sample size does not always increase the predictive power to a
desired level. Moreover, because this is an average power, smaller values are usually expected.
Furthermore, as many replications are being conducted and only a fraction confirms the original result,
we argue for the necessity of sequentially analyzing the results. With this in mind, we encourage the
initiative from Camerer et al. (2018) to terminate some replication studies prematurely based on an interim
analysis. However, their approach only enables efficacy stopping. We propose to use interim power to
judge if a replication study should be stopped for futility. Interim analyses can help to save time and
resources but also raise new questions with regard to the choice of prior distributions. We have shown using
studies from the SSRP that different design priors lead to very different power values and by extension to
different decisions. Conditioning the power calculations at interim on the original results is even more
unreasonable than at the study start and leads to very large power values given a significant original result,
even if interim results suggest evidence in the opposite direction. Predictive power calculations are thus
also the preferred alternative at interim.
Some limitations should be noted. First, while the ICH E9 ‘Statistical Principles for Clinical Trials’ (ICH
E9 Expert Working Group, 1999) recommends blinded interim results, our data at interim are assumed to be
completely unblinded. This is not a problem in the present case of a one-sample test but becomes an issue
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Figure 6: Informed predictive power at interim (IPPi) and predictive power at interim (PPi) as a function
of the fraction 1 − f of the replication study still to be completed for the studies of Table 1 and with two
hypothetical interim p-values. Horizontal lines represent asymptotes of IPPi and PPi with pi = 0.5 (black)
and pi = 0.03 (red).
when we want to compare two groups. Such a situation would require an Independent Data Monitoring
Committee to prevent the replication study from being biased (Kieser and Friede, 2003). This issue has
extensively been covered in the clinical trials literature (Kieser and Friede, 2003; Bauer and König, 2006).
Second, we have shown that interim power is performant for futility decisions but is similar to the approach
from Camerer et al. (2018) for efficacy decisions. Furthermore, only one interim analysis is considered in
our approach and the strong assumption of normality is made. Further research will focus on extending
this framework to more than one interim analysis by replication study and to other settings such as the
t-test. It will also be of interest to develop the concepts discussed in Section 4 within the reverse-Bayes
framework (Held, 2020).
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Software for these power calculations can be found in the R-package ReplicationSuccess, available
at https://r-forge.r-project.org/projects/replication/. An example of the usage of this
package is given in Appendix C.
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A Non-sequential replication study
A.1 Conditional power
Suppose researchers conducted a study and declared the results significant at a pre-specified level α. In
order to confirm this finding, a replication study is planned. Let us assume that the future data of the
replication study are normally distributed as follows,
Y1, . . . , Ynr
iid∼ N
(
θ, σ2
)
,
where θ is the true effect size and σ is the known standard deviation of one observation. Let the sample
mean of Y1:nr be the parameter estimate of the replication study. The parameter estimateYnr has distribu-
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tion
Ynr ∼ N
(
θ, σ2/nr
)
, (14)
with nr being the planned sample size in the replication study. Let us suppose the null hypothesis of the
replication study is H0: θ = 0 and we want to detect an alternative hypothesis H1: θ = θˆo > 0, where
θˆo is the effect estimate of the original study. The corresponding standardized test statistic tr is Ynr
√
nr/σ
and we declare the result statistically significant at the two-sided α level if |tr| > z1−α/2 = −zα/2. In the
following, we focus on tr > −zα/2 as tr < zα/2 is relatively small for θˆo > 0. H0 will thus be rejected when
the parameter estimateYnr obeys
Ynr > −
1√
nr
zα/2σ .
This event is denoted by SCα/2 and is called the ‘classical significance’ (Spiegelhalter et al., 2004, Section 6.5.2)
as a classical (frequentist) analysis will be conducted at the end of the replication study and is opposed to
‘Bayesian significance’ (Spiegelhalter et al., 2004, Section 6.5.3) which will become a relevant concept in A.3.
Under H1,Ynr is normally distributed with mean E
(
Ynr
)
= θˆo and variance Var
(
Ynr
)
= σ2/nr. In order
to calculate the power of the replication study, we compute the probability of ‘classical significance’ given
that the effect estimate of the original study is the true effect,
Pr
(
SCα/2 | θ = θˆo
)
= Pr
(
Ynr > −
1√
nr
zα/2σ
)
= 1− Pr
(
Ynr ≤ −
1√
nr
zα/2σ
)
= 1− Pr
Ynr − E(Ynr )√
Var(Ynr )
≤ −zα/2σ/
√
nr − E(Ynr )√
Var(Ynr )

= 1− Φ
−zα/2σ/√nr − E(Ynr )√
Var(Ynr )

= Φ
zα/2σ/√nr + E(Ynr )√
Var(Ynr )

= Φ
[
zα/2σ/
√
nr + θˆo√
σ2/nr
]
= Φ
[
θˆo
√
nr
σ
+ zα/2
]
. (15)
Equation (15) specifies the conditional power of a replication study with nr subjects assuming a classical
analysis of the results. The necessary sample size to achieve a pre-specified level of power in the replication
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study can be derived from equation (15) and is given by
nr =
(z1−β − zα/2)2σ2
θˆ2o
,
where 1− β denotes the power and z1−β the (1− β)-quantile of the standard normal distribution for nota-
tional simplicity.
A.2 Predictive power
As a classical analysis is performed at the end of the replication study, we again calculate the probability of
‘classical significance’. However, in this case the conditional probability needs to be integrated with respect
to the design prior θ ∼ N
(
θˆo, σ
2/no
)
. Integration can be demanding and a more direct way is to use the
predictive distribution ofYnr ,
Ynr ∼ N
(
θˆo, σ
2 (1/no + 1/nr)
)
, (16)
obtained by combining the prior and the likelihood (14). The predictive power is
Pr
(
SCα/2
)
= Pr
(
Ynr > −
1√
nr
zα/2σ
)
.
The design prior is incorporated by using the predictive distribution (16) ofYnr ,
Pr
(
SCα/2
)
= 1− Φ
−zα/2σ/√nr − E(Ynr )√
Var(Ynr )

= Φ
[
zα/2σ/
√
nr + θˆo
σ
√
1/no + 1/nr
]
= Φ
[√
no
no + nr
(
θˆo
√
nr
σ
+ zα/2
)]
.
A.3 Fully Bayesian power
Similarly to Pr
(
SCα/2
)
the probability of ‘classical significance’ which is the power in the case of a frequen-
tist analysis, we need to calculate Pr
(
SBα/2
)
, the probability of ‘Bayesian significance’. ‘Bayesian signifi-
cance’ is denoted as
SBα/2 = Pr (θ < 0 | replication data) < α/2
and is the predictive probability of obtaining a significant Bayesian result when testing the null hypothesis
θ < 0 against an alternative θ > 0. Assuming a future parameter estimateYnr , the posterior distribution of
θ is given by
θ |Ynr ∼ N
(
noθˆo + nrYnr
no + nr
,
σ2
no + nr
)
.
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In words, Bayesian significance SBα/2 means that the α/2-quantile of the posterior distribution of θ |Ynr is
larger than zero. Let zα/2 be the α/2-quantile of the standard normal distribution. The α/2-quantile of
θ |Ynr is
zα/2σ√
no + nr
+ noθˆo + nrYnr
no + nr
.
‘Bayesian significance’ is then
SBα/2 ⇔
zα/2σ√
no + nr
+ noθˆo + nrYnr
no + nr
> 0 ,
which can be rearranged as
Ynr >
−√no + nrzα/2σ − noθˆo
nr
.
The fully Bayesian power is then
Pr
(
SBα/2
)
= Pr
(
Ynr >
−√no + nrzα/2σ − noθˆo
nr
)
.
We again incorporate the design prior by using the predictive distribution (16) ofYnr ,
Pr
(
SBα/2
)
= 1− Φ
−√no + nrzα/2σ − noθˆo − nr E(Ynr )
nr
√
Var(Ynr )

= 1− Φ
[
−√no + nrzα/2σ − noθˆo − nr θˆo
nrσ
√
(no + nr)/nrno
]
= Φ
[
θˆo
√
no
√
no + nr
σ
√
nr
+
√
no
nr
zα/2
]
. (17)
Equation (17) can be rewritten in terms of the original test statistic to = θˆo/σo = θˆo
√
no/σ and the relative
sample size c = σ2o/σ2r = (σ2/no)/(σ2/nr) = nr/no:
FBP = Φ
[√
c+ 1
c
to +
√
1
c
zα/2
]
. (18)
24
A.4 Conditional Bayesian power
The conditional Bayesian power is the probability of ‘Bayesian significance’ conditioned on the effect esti-
mate from the original study,
Pr
(
SBα/2 | θ = θˆo
)
= Pr
(
Ynr >
−√no + nrzα/2σ − noθˆo
nr
)
= 1− Φ
−√no + nrzα/2σ − noθˆo − nr E(Ynr )
nr
√
Var(Ynr )

= 1− Φ
[
−√no + nrzα/2σ − noθˆo − nr θˆo
nrσ/
√
nr
]
= Φ
[√
no + nr
nr
zα/2 +
θˆo(no + nr)
σ
√
nr
]
. (19)
Equation (19) can be rewritten in terms of to and c:
CBP = Φ
[
c+ 1√
c
to +
√
c+ 1
c
zα/2
]
.
A.5 Conditional vs. predictive power
A.5.1 Conditional vs. predictive power
We want to know when Pr
(
SCα/2 | θ = θˆo
)
= Pr
(
SCα/2
)
, which is equivalent to
Φ
[
θˆo
√
nr
σ
+ zα/2
]
= Φ
[√
no
no + nr
(
θˆo
√
nr
σ
+ zα/2
)]
⇔ θˆo
√
nr
σ
+ zα/2 =
√
no
no + nr
(
θˆo
√
nr
σ
+ zα/2
)
⇔ nr = 0 or nr =
σ2z2α/2
θˆ2o
⇔ c = 0 or c =
z2α/2
t2o
.
By plugging σ2z2α/2/θˆo in the conditional (or predictive) power formula, we obtain the replication power
corresponding to the intersection of both power curves,
Φ
[
θˆo
√
nr
σ
+ zα/2
]
= Φ
 θˆo
√
σ2z2α/2/θˆ
2
o
σ
+ zα/2

= Φ
 θˆo
∣∣∣σzα/2/θˆo∣∣∣
σ
+ zα/2

= Φ
[∣∣zα/2∣∣+ zα/2]
= 0.5 .
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Because σ is always positive, zα/2 is always negative and θˆo is assumed to be positive, the formula can be
simplified.
A.5.2 Conditional Bayesian vs. fully Bayesian power
We want to know when Pr
(
SBα/2 | θ = θˆo
)
= Pr
(
SBα/2
)
, which is equivalent to
Φ
[√
no + nr
nr
zα/2 +
θˆo(no + nr)
σ
√
nr
]
= Φ
[
θˆo
√
no
√
no + nr
σ
√
nr
+
√
no
nr
zα/2
]
⇔
√
no + nr
nr
zα/2 +
θˆo(no + nr)
σ
√
nr
= θˆo
√
no
√
no + nr
σ
√
nr
+
√
no
nr
zα/2
⇔ nr =
σ2z2α/2 − θˆ2ono
θˆ2o
⇔ c =
z2α/2
t2o
− 1 . (20)
By plugging the replication sample size corresponding to (20) in the fully Bayesian power formula (5), we
once again retrieve a power of 50%.
A.6 Asymptote of predictive power
lim
c→∞PP = limc→∞Φ
[√
1
c+ 1
(
to
√
c+ zα/2
)]
= Φ[to] .
A.7 Minimum fully Bayesian power
As the function Φ[·] is monotonically increasing, considering its argument is sufficient when manipulating
it. The first derivative of the fully Bayesian power formula is
d
dnr
(
θˆo
√
no
√
no + nr
σ
√
nr
+
√
no
nr
zα/2
)
=
θˆo
√
no( 12 (no + nr)−1/2σ
√
nr − 12 (no + nr)1/2)
σ2nr
+√nozα/2n−3/2r
(
−12
)
=
1/2√non−3/2r
(
θˆonr(no + nr)−
1
2
σ
− θˆo(no + nr)
1/2
σ
− zα/2
)
.
By setting it to 0 and solving for nr, we obtain the replication sample size nr needed to reach the minimum
power, which turns out to be
1
2
√
non
− 32
r
(
θˆonr(no + nr)−
1
2
σ
− θˆo(no + nr)
1
2
σ
− zα/2
)
= 0 ⇔ nr = no
(
θˆ2ono
σ2z2α/2
− 1
)
⇔ c = t
2
o
z2α/2
− 1 . (21)
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By plugging (21) in the alternative fully Bayesian power formula given in (18), we find the corresponding
minimum fully Bayesian power which is
Pr(SBα/2) = Φ
[√
t2o − z2α/2
]
.
B Sequential replication studies
B.1 Conditional power at interim
The following notation is used: no and θˆo define the sample size and effect estimate in the original study, ni
and θˆi the sample size and the effect estimate at the interim analysis, nj the number of additional subjects to
be collected in the replication study andYnj the corresponding parameter estimate. The common standard
deviation of one observation is denoted by σ and is assumed to be known and the same in the original and
the replication study. We have
niθˆi + njYnj
ni + nj
∼ N
(
θ,
σ2
ni + nj
)
.
From this we can calculate the ‘classical significance’, which is
Ynj >
−√ni + njzα/2σ − niθˆi
nj
.
The conditional power at interim is the probability of ‘classical significance’ conditioned on the effect esti-
mate from the original study:
Pr
(
SCα/2 | θˆi, θ = θˆo
)
= Pr
(
Ynj >
−√ni + njzα/2σ − niθˆi
nj
)
= Φ
[√
nj θˆo
σ
+ niθˆi
σ
√
nj
+
√
ni + nj
nj
zα/2
]
(22)
Let the original and interim test statistics be to = θˆo/σo = θˆo
√
no/σ and ti = θˆi/σi = θˆi
√
ni/σ, the relative
sample size c = nr/no = (ni + nj)/no and the fraction of the replication study completed so far be f =
ni/nr = ni/(ni + nj). Then, Equation (22) can be rewritten in terms of to, ti, c and f :
CPi = Φ
[√
c(1− f) to +
√
f
1− f ti +
√
1
1− f zα/2
]
. (23)
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B.2 Informed predictive power at interim
The informed predictive power at interim is the predictive probability of ‘classical significance’,
Pr
(
SCα/2
)
= Φ
[√
nonj
(no + ni)(no + ni + nj)
√
noθˆo
σ
+
√
ni (no + ni + nj)
nj (no + ni)
√
niθˆi
σ
+
√
(ni + nj) (no + ni)
nj (no + ni + nj)
zα/2
]
.
which can be rewritten as
IPPi = Φ
[√
(1− f)c
(cf + 1)(1 + c) to +
√
f(1 + c)
(1− f)(cf + 1) ti +
√
cf + 1
(1 + c)(1− f) zα/2
]
. (24)
B.3 Predictive power at interim
The PPi formula can be found by setting no = 0 in the IPPi formula in (24), which results in
Pr
(
SCα/2
)
= Φ
[√
ni + nj
nj
√
niθˆi
σ
+
√
ni
nj
zα/2
]
. (25)
Equivalently,
PPi = Φ
[√
1
1− f ti +
√
f
1− f zα/2
]
.
Equation (25) is identical to (17) given that ni = no, nj = nr and θˆi = θˆo.
B.4 Fully Bayesian power at interim
We need to calculate Pr
(
SBα/2
)
, the probability of ‘Bayesian significance’. ‘Bayesian significance’, in this
case, is denoted as
SBα/2 = Pr
(
θ < 0 | θˆi, replication data
)
< α/2
Assuming a future parameter estimateYn, the posterior distribution of θ is given by
θ |Ynj ∼ N
(
noθˆo + niθˆi + njYnj
no + ni + nj
,
σ2
no + ni + nj
)
.
‘Bayesian significance’ is then
Ynj >
−√no + ni + njzα/2σ − (noθˆo + niθˆi)
nj
.
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The fully Bayesian power at interim is then
Pr
(
Ynj >
−√no + ni + njzα/2σ − (noθˆo + niθˆi)
nj
)
.
Using the predictive distribution ofYnj | θˆi,
Ynj | θˆi ∼ N
(
noθˆo + niθˆi
no + ni
, σ2
(
1
no + ni
+ 1
nj
))
,
the fully Bayesian power at interim turns out to be
Pr
(
SBα/2
)
= Φ
[√
no + ni + nj
(no + ni)nj
noθˆo + niθˆi
σ
+
√
no + ni
nj
zα/2
]
.
Equivalently,
FBPi = Φ
[√
1 + c(1− f)(cf + 1)
√
1
c(1− f) to +
√
1 + c(1− f)(cf + 1)
√
f
1− f ti +
√
(cf + 1)
c(1− f) zα/2
]
.
B.5 Weights given to original and interim results
B.5.1 CPi
In the CPi formula in (23), more weight is given to the original result if
√
c(1− f) >
√
f
1− f
⇔ c(1− f) > f1− f
⇔ c > f(1− f)2
B.5.2 IPPi
In the IPPi formula in (24), more weight is given to the original result if
√
(1− f)c
(cf + 1)(1 + c) >
√
f(1 + c)
(1− f)(cf + 1)
⇔ c(c+ 1)2 >
f
(1− f)2
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B.6 Asymptotes
lim
nj→∞
CPi =∞
lim
nj→∞
IPPi = Φ
[√
1
ni/no + 1
to +
√
ni/no
ni/no + 1
ti
]
lim
nj→∞
PPi = Φ [ti]
B.7 Minimum PPi
As the PPi formula in (25) is identical to the fully Bayesian power formula in (17) given that ni = no, nj = nr
and θˆi = θˆo, the minimum PPi is simply Φ
[√
t2i − z2α/2
]
.
C Package ReplicationSuccess
Installation
# install the package
install.packages("ReplicationSuccess",
repos = "http://R-Forge.R-project.org")
# load the package
library("ReplicationSuccess")
Data
# load the data
data(SSRP)
Table 5 shows the main variables of the SSRP dataset.
Functions
The two main functions that were used in this paper are powerSignificance and powerSignificanceInterim.
The main arguments of these functions are presented in Table 6.
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study Authors of the original paper
ro Original effect on correlation scale
ri Interim effect on correlation scale
rr Replication effect on correlation scale
fiso Original effect on Fisher-z scale
fisi Interim effect on Fisher-z scale
fisr Replication effect on Fisher-z scale
se_fiso Standard error of fiso
se_fisi Standard error of fisi
se_fisr Standard error of fisr
no Nominal sample size in original study
ni Nominal sample size in replication study at interim
nr Nominal sample size in replication study at the final analysis
po Two-sided p-value from original study
pi Two-sided p-value from interim analysis
pr Two-sided p-value from replication study
Table 5: Main variables of the SSRP dataset.
zo z-value from original study
zi z-values from interim analysis
c Ratio of the replication sample size to the original sample size
f Fraction of the replication study already completed
designPrior Design prior
analysisPrior Analysis prior
alternative Direction of the alternative
level Significance level
shrinkage Shrinkage factor for original effect estimate
Table 6: Arguments of the powerSignificance and powerSignificanceInterim functions. Argu-
ments only used in powerSignificanceInterim are in grey.
Examples
# Variables
# z-value from original study
SSRP$zo = SSRP$fiso/SSRP$se_fiso
# z-value at interim
SSRP$zi = SSRP$fisi/SSRP$se_fisi
# relative sample size from figure 3,
# where stage 2 is ignored
# (results at interim are considered
# final results)
SSRP$c_f3 = (SSRP$ni - 3)/(SSRP$no - 3)
# same values can be found
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# with variance ratio
# SSRP$c_f3 = SSRP$se_fiso^2/SSRP$se_fisi^2
# relative sample size
SSRP$c = (SSRP$nr - 3)/(SSRP$no - 3)
# same values with variance ratio
# SSRP$c = SSRP$se_fiso^2/SSRP$se_fisr^2
# fraction of replication study
# already completed
SSRP$f = (SSRP$ni - 3)/(SSRP$nr - 3)
# same result
# with variance ratio
# SSRP$f = SSRP$se_fisr^2/SSRP$se_fisi^2
# Example : calculation of the predictive power
# from Figure 3
powerSignificance(zo = SSRP$zo,
c = SSRP$c_f3,
designPrior = "predictive",
shrinkage = 0.25,
alternative = "two.sided",
level = 0.05)
# Example: calculation of the informed predictive power
# at interim (IPPi) from Table 4
# select the studies that were continued
# after the interim analysis
SSRP_cont <- SSRP[!is.na(SSRP$rr),]
powerSignificanceInterim(zo = SSRP_cont$zo,
zi = SSRP_cont$zi,
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c = SSRP_cont$c,
f = SSRP_cont$f,
designPrior = "informed predictive",
analysisPrior = "flat",
alternative = "two.sided",
level = 0.05)
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